ARS Pharmaceuticals
SPRY
SPRY
150 hedge funds and large institutions have $928M invested in ARS Pharmaceuticals in 2024 Q3 according to their latest regulatory filings, with 48 funds opening new positions, 58 increasing their positions, 23 reducing their positions, and 12 closing their positions.
New
Increased
Maintained
Reduced
Closed
more first-time investments, than exits
New positions opened: | Existing positions closed:
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more capital invested
Capital invested by funds: $ → $
more call options, than puts
Call options by funds: $ | Put options by funds: $
50% more funds holding in top 10
Funds holding in top 10: 2 → 3 (+1)
30% more funds holding
Funds holding: 115 → 150 (+35)
1.48% more ownership
Funds ownership: 64.59% → 66.08% (+1.5%)
Holders
150
Holding in Top 10
3
Calls
$14.2M
Puts
$9.25M
Top Buyers
| 1 | +$10.2M | |
| 2 | +$8.6M | |
| 3 | +$7.79M | |
| 4 |
Morgan Stanley
New York
|
+$7.32M |
| 5 |
Millennium Management
New York
|
+$7.06M |
Top Sellers
| 1 | -$34M | |
| 2 | -$13.8M | |
| 3 | -$11.6M | |
| 4 |
PA
Perceptive Advisors
New York
|
-$7.38M |
| 5 |
RCMNY
Rubric Capital Management (New York)
New York
|
-$5.44M |